Targeted Cancer Chemotherapy: Pharmacology Chapter

Introduction/Overview

Targeted therapies have transformed the therapeutic landscape of oncology by offering precision approaches that interfere with specific molecular pathways essential for malignant cell survival and proliferation. Unlike conventional cytotoxic agents that indiscriminately damage rapidly dividing cells, these agents are designed to exploit genetic, proteomic, or metabolic abnormalities characteristic of tumor cells. Consequently, therapeutic indices are improved, and off‑target toxicities are often reduced, although resistance mechanisms frequently emerge.

Clinical relevance is underscored by the increasing number of FDA‑approved targeted agents across diverse malignancies, including epidermal growth factor receptor (EGFR) inhibitors for non‑small cell lung cancer, B‑cell lymphoma 2 (BCL‑2) antagonists for chronic lymphocytic leukemia, and immune checkpoint inhibitors that modulate T‑cell activity. The ability to tailor therapy based on tumor biomarker status has become a cornerstone of modern oncology practice, necessitating a deep understanding of pharmacology for both clinicians and pharmacists.

Learning objectives for this chapter are as follows:

• Identify the principal classes of targeted anticancer agents and their molecular targets.
• Describe the pharmacodynamic principles underlying selective tumor inhibition.
• Explain the key pharmacokinetic parameters influencing dosing and therapeutic monitoring.
• Recognize approved indications and off‑label uses for representative targeted therapies.
• Summarize common adverse effect profiles and strategies for mitigating toxicity.

Classification

Drug Classes and Molecular Targets

Targeted therapies can be broadly grouped according to their primary mechanism of action and the molecular entity they engage:

• Tyrosine Kinase Inhibitors (TKIs) – Small molecules that competitively inhibit ATP binding sites on receptor or non‑receptor tyrosine kinases (e.g., imatinib, erlotinib, sunitinib).
• Monoclonal Antibodies (mAbs) – Recombinant antibodies that bind extracellular domains of cell surface proteins or soluble ligands (e.g., trastuzumab, cetuximab, bevacizumab).
• Antibody‑Drug Conjugates (ADCs) – mAbs linked to cytotoxic payloads, delivering the drug selectively to antigen‑expressing cells (e.g., brentuximab vedotin).
• Immune Checkpoint Inhibitors (ICIs) – Antibodies that block inhibitory receptors on T cells or ligands on tumor cells (e.g., nivolumab, pembrolizumab, ipilimumab).
• Proteasome Inhibitors – Small molecules that disrupt proteasomal degradation pathways (e.g., bortezomib, carfilzomib).
• Small‑Molecule Inhibitors of Specific Oncogenic Drivers – Agents targeting mutant proteins (e.g., vemurafenib for BRAF V600E, crizotinib for ALK rearrangements).

Chemical Classification

From a chemical standpoint, TKIs are predominantly heterocyclic compounds with high affinity for ATP‑binding clefts, whereas mAbs are proteinaceous with defined antigen‑binding fragments (Fab). ADCs combine both modalities, employing a linker chemistry that ensures stability in circulation but permits payload release within the target cell. Proteasome inhibitors often contain boronic acid or epoxyketone moieties that covalently engage the proteolytic site. The diversity of chemical scaffolds underpins the specificity and pharmacokinetic properties unique to each class.

Mechanism of Action

Pharmacodynamics of Tyrosine Kinase Inhibitors

TKIs exert their effect by occupying the ATP‑binding pocket of tyrosine kinases, thereby preventing phosphorylation cascades that drive oncogenic signaling. For example, imatinib binds to the inactive conformation of BCR‑ABL, stabilizing the kinase in a non‑catalytic state. This inhibition results in decreased downstream activation of pathways such as RAS‑MAPK and PI3K‑AKT, culminating in reduced proliferation and increased apoptosis of malignant cells.

Binding affinity (K_d) and selectivity ratios are critical determinants of therapeutic efficacy and safety. In vitro studies demonstrate that high selectivity for mutant versus wild‑type kinases correlates with improved tumor control and lower myelosuppression. Additionally, allosteric inhibitors that bind sites distinct from the ATP pocket (e.g., ibrutinib’s covalent interaction with BTK) offer irreversible blockade, which can overcome resistance mutations that preserve ATP affinity.

Monoclonal Antibody Target Engagement

mAbs typically recognize extracellular epitopes of surface receptors or secreted ligands, blocking ligand binding or inducing receptor internalization. Trastuzumab binds to domain IV of HER2, preventing homodimerization and recruiting antibody‑dependent cellular cytotoxicity (ADCC) via Fcγ receptors on natural killer cells. Cetuximab targets EGFR, inhibiting ligand‑induced activation and promoting receptor down‑regulation. Bevacizumab binds vascular endothelial growth factor (VEGF), neutralizing its angiogenic activity and impairing tumor vascularization.

Antibody‑Drug Conjugates

ADCs combine the targeting specificity of mAbs with the potency of cytotoxic agents. The linker chemistry dictates pharmacokinetics and release kinetics. For instance, brentuximab vedotin employs a protease‑cleavable valine‑citrulline linker that releases monomethyl auristatin E (MMAE) within CD30‑positive cells. The internalized antibody is degraded in lysosomes, liberating the microtubule‑inhibiting payload, which induces mitotic arrest and apoptosis.

Immune Checkpoint Inhibitors

ICIs restore antitumor immunity by blocking inhibitory pathways that dampen T‑cell activation. Nivolumab and pembrolizumab bind PD‑1, preventing engagement with PD‑L1/PD‑L2 expressed on tumor cells, thereby sustaining T‑cell cytotoxicity. Ipilimumab targets CTLA‑4, augmenting priming of T cells in lymphoid tissues. The resulting immune activation can lead to durable remissions but also precipitates immune‑mediated adverse events.

Proteasome Inhibitors

Proteasome inhibitors bind the catalytic threonine residue in the β5 subunit of the 20S proteasome, blocking the chymotrypsin‑like activity essential for degradation of short‑lived regulatory proteins. Inhibition leads to accumulation of misfolded proteins and activation of the unfolded protein response, triggering apoptosis preferentially in plasma cells due to their high protein synthesis burden.

Pharmacokinetics

Absorption

Oral TKIs generally exhibit variable bioavailability, influenced by gastric pH, food intake, and transporter activity (e.g., P‑gp, OATP). For example, erlotinib’s absorption is enhanced by high‑fat meals, whereas gefitinib is best taken on an empty stomach. Parenteral mAbs and ADCs bypass absorption barriers, achieving immediate systemic exposure upon intravenous infusion. Subcutaneous administration of some mAbs (e.g., trastuzumab) results in a slower absorption phase, with C_max typically reached within 24–48 h.

Distribution

Volume of distribution (V_d) varies markedly across classes. Small‑molecule TKIs often have extensive tissue penetration (V_d > 10 L kg⁻¹), facilitating tumor access. In contrast, mAbs have limited extravascular distribution due to their size, with V_d approximating plasma volume (≈ 3–4 L kg⁻¹). ADCs inherit the distribution characteristics of their antibody component, but the cytotoxic payload may diffuse into surrounding tissues after linker cleavage.

Metabolism

Metabolic pathways are predominantly hepatic. TKIs undergo oxidative metabolism via cytochrome P450 isoenzymes (CYP3A4, CYP2D6), with some agents (e.g., imatinib) also metabolized by CYP2C8. mAbs are degraded proteolytically, yielding small peptides and amino acids. ADCs may release the cytotoxic payload through enzymatic cleavage of the linker; the released drug is subsequently metabolized via standard hepatic routes.

Excretion

Renal clearance is significant for many TKIs (e.g., gefitinib, sorafenib). Excretion of mAbs occurs via reticuloendothelial system catabolism rather than glomerular filtration. For ADCs, the fate of the released payload is governed by its own pharmacokinetics, often involving renal elimination of metabolites.

Half‑Life and Dosing Considerations

The elimination half‑life (t_1/2) informs dosing intervals. Oral TKIs typically require daily dosing (t_1/2 ≈ 10–30 h), whereas mAbs can be dosed every 2–4 weeks due to longer t_1/2 (≈ 7–10 days). ADCs may necessitate intermittent dosing schedules (e.g., every 3 weeks) to allow recovery from cytotoxic exposure. Dose adjustments are warranted in hepatic or renal impairment; for example, sorafenib dose is reduced by 50 % in patients with Child‑Pugh B cirrhosis, and erlotinib is dosed at 50 % of the standard dose in creatinine clearance < 30 mL min⁻¹.

Therapeutic Uses/Clinical Applications

Approved Indications

Representative agents and their primary indications include:

• Imatinib – Chronic myeloid leukemia, gastrointestinal stromal tumors (GIST) with KIT mutations.
• Erlotinib – EGFR‑mutant non‑small cell lung cancer (NSCLC).
• Trastuzumab – HER2‑positive breast cancer (adjuvant and metastatic).
• Pembrolizumab – Melanoma, NSCLC, urothelial carcinoma, Hodgkin lymphoma.
• Brentuximab vedotin – CD30‑positive Hodgkin lymphoma, systemic anaplastic large cell lymphoma.
• Bortezomib – Multiple myeloma.
• Crizotinib – ALK‑rearranged NSCLC, ROS1‑positive NSCLC.
• Vemurafenib – BRAF V600E mutant melanoma.

Off‑Label Uses

Off‑label utilization is common, driven by emerging evidence or lack of approved options. For example, dabrafenib and trametinib are combined in BRAF‑mutant colorectal cancer, and bevacizumab is employed in metastatic colorectal cancer despite limited phase III data. Off‑label indications are often guided by biomarker testing and multidisciplinary tumor board recommendations.

Adverse Effects

Common Side Effects

Side effect profiles differ by class but frequently include:

• TKIs – Diarrhea, nausea, skin rash, edema, QT prolongation (e.g., sunitinib).
• mAbs – Infusion reactions (fever, chills, hypotension), injection site erythema, mucositis (e.g., trastuzumab).
• ICIs – Immune‑related adverse events: colitis, hepatitis, endocrinopathies (hypophysitis, thyroiditis), pneumonitis.
• ADC Payloads – Peripheral neuropathy, myelosuppression, ocular toxicity (e.g., brentuximab vedotin).
• Proteasome Inhibitors – Peripheral neuropathy, thrombocytopenia, gastrointestinal upset.

Serious or Rare Adverse Reactions

Serious events, though less common, require vigilance:

• Cardiotoxicity (e.g., trastuzumab‑induced congestive heart failure).
• Severe interstitial lung disease with TKIs (e.g., gefitinib).
• Immune‑mediated colitis and enterocolitis with ICIs.
• Severe hypersensitivity reactions to mAbs.
• Secondary malignancies associated with prolonged TKIs.

Black Box Warnings

Black box warnings are issued for agents with high morbidity or mortality risks. For instance, bevacizumab carries a warning for gastrointestinal perforation and hemorrhage. ICIs have warnings regarding immune‑related adverse events that may be fatal if untreated. These warnings necessitate patient education and close monitoring.

Drug Interactions

Major Drug‑Drug Interactions

Interactions are primarily mediated by hepatic enzymes or transporters:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase plasma concentrations of TKIs such as erlotinib, potentially exacerbating toxicity.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy of TKIs by enhancing metabolism.
• Anticoagulants (e.g., warfarin) can be affected by TKIs that alter hepatic metabolism of vitamin K.
• Concomitant use of multiple ICIs may amplify immune‑related adverse events.
• Certain mAbs (e.g., trastuzumab) may interact with agents that affect cardiac function, necessitating dose adjustments.

Contraindications

Contraindications include hypersensitivity to the drug or excipients, uncontrolled cardiovascular disease for agents with cardiotoxic potential, and significant hepatic dysfunction for drugs with hepatic metabolism. For example, trastuzumab is contraindicated in patients with left ventricular ejection fraction (LVEF) below 45 %.

Special Considerations

Use in Pregnancy and Lactation

Targeted agents are generally contraindicated during pregnancy due to teratogenic potential and lack of safety data. Animal studies often reveal fetal toxicity. Lactation is discouraged for most agents; however, limited data exist for some TKIs, and the decision should involve risk‑benefit assessment and patient counseling.

Pediatric and Geriatric Considerations

Pediatric dosing often requires weight‑based calculations, and pharmacokinetics can differ due to developmental changes in enzyme activity. Geriatric patients may exhibit altered drug clearance, increased susceptibility to toxicity, and comorbidities that influence drug selection. Dose adjustments and therapeutic drug monitoring are advisable in both populations.

Renal and Hepatic Impairment

Renal impairment may necessitate dose reduction or increased dosing intervals for agents cleared renally. Hepatic impairment, particularly severe cirrhosis, can lead to accumulation of hepatically metabolized TKIs, mandating careful monitoring and dose modification. For drugs with both hepatic and renal elimination, a combined assessment is required.

Summary/Key Points

• Targeted therapies selectively inhibit oncogenic drivers, improving therapeutic indices compared with conventional cytotoxic chemotherapy.
• Mechanistic diversity spans kinase inhibition, antibody blockade, immune checkpoint modulation, and proteasome inhibition.
• Pharmacokinetic profiles influence dosing frequency, route of administration, and need for therapeutic monitoring.
• Adverse effect profiles vary by class; vigilant monitoring for cardiotoxicity, immune‑mediated events, and neuropathies is essential.
• Drug interactions, especially involving CYP3A4, can significantly alter exposure and necessitate dose adjustments.
• Special populations—including pregnant patients, pediatrics, geriatrics, and those with organ dysfunction—require individualized management strategies.
• Ongoing research into resistance mechanisms and combination regimens promises to refine the therapeutic landscape further.

References

1. Chabner BA, Longo DL. Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice. 6th ed. Philadelphia: Wolters Kluwer; 2019.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.